<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967954</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000639017</org_study_id>
    <secondary_id>CRUK-CHIRRP</secondary_id>
    <secondary_id>EU-20920</secondary_id>
    <nct_id>NCT00967954</nct_id>
  </id_info>
  <brief_title>Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer</brief_title>
  <official_title>A Study of Changes in the Prostate Following Androgen Deprivation to Investigate Therapy Response and Resistance in Clinical Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory&#xD;
      may help doctors learn more about changes that occur in DNA and identify biomarkers related&#xD;
      to cancer. It may also help doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This research study is looking at blood and tissue samples from patients with&#xD;
      prostate cancer receiving androgen deprivation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To identify the molecular and pathophysiological changes which occur during the early&#xD;
           stages of androgen deprivation (AD) and during emerging castration-resistant prostate&#xD;
           cancer.&#xD;
&#xD;
        -  To test functional imaging as a non-invasive tool to measure treatment response and&#xD;
           validate this using biological endpoints.&#xD;
&#xD;
        -  To develop clinical models to predict how tumors will respond to AD and identify new&#xD;
           targets once AD fails.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Group A: Patients likely to receive androgen deprivation (AD) as first-line therapy&#xD;
           undergo blood and prostate biopsy sample collection before and after treatment on days 0&#xD;
           and 14 or 90. Patients receive an androgen receptor inhibitor followed by maintenance&#xD;
           with a gonadotropin-releasing hormone analogue beginning on day 0. Patients also undergo&#xD;
           diffusion-weighted MRI, MR spectroscopic imagining, quantitative T1W mapping, and T1W&#xD;
           perfusion sequence.&#xD;
&#xD;
        -  Group B: Patients already receiving AD undergo blood and prostate biopsy sample&#xD;
           collection within 4 weeks of diagnosis of castration-resistant prostate cancer and&#xD;
           before initiating any second-line therapy.&#xD;
&#xD;
      Blood and tissue samples are assessed via DNA and RNA genetic analysis, gene expression&#xD;
      studies, and comparative genomic hybridization to identify novel markers of androgen response&#xD;
      and resistance.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of molecular and pathophysiological changes</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional imaging as a non-invasive tool to measure treatment response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of clinical models to predict tumor response</measure>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiandrogen therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>releasing hormone agonist therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>comparative genomic hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  High clinical suspicion of prostate cancer, based on an abnormal digital rectal&#xD;
                  examination and PSA (&gt; 20 ng/mL)&#xD;
&#xD;
               -  Newly diagnosed, castration-resistant prostate cancer&#xD;
&#xD;
                    -  Clinical stage â‰¥ T2c disease&#xD;
&#xD;
          -  Significant tumor volume on initial diagnostic biopsy (&gt; 50% of cores)&#xD;
&#xD;
          -  Likely to receive androgen deprivation therapy for prostate cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No contraindication to transrectal needle biopsy&#xD;
&#xD;
          -  No contraindication to MRI or prostate needle biopsy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Gnanapragasam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Research UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research UK at Cambridge Research Institute</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Gnanapragasam, MD</last_name>
      <phone>44-1223-348-363</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Androgen Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

